Clinical-stage oncology biotechnology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters
Clinical-stage oncology biotechnology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. The drug was studied in Phase 1/2 combination trials, including for advanced ovarian cancer. The company also describes its work as developing next-generation synthetically lethal cancer therapies.